Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Six-month data back Biotronik's absorbable metal stent:

This article was originally published in Clinica

Executive Summary

Six-month follow-up studies from the first human trials of an absorbable metal stent (AMS) developed by Biotronik, have shown the device to be safe and effective when used to treat blocked arteries below the knee. Only one of the 20 stent recipients needed an amputation during the follow-up period, the Berlin, Germany firm said, adding that this was an "excellent" outcome since all the patients were high-risk. Some 79% of each stented vessel remained patent, indicating that the arteries remained stabilised even after the stent had been absorbed, a process that takes between two and three months to complete.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel